Conference:  Transform X 2021

Authors: Daphne Koller

2021-10-07

The speaker discusses the field of digital biology and its potential to shape the next 30 years of science, particularly in the discovery and development of medicines. They explain the concept of end-to-end learning and reducing the dimensionality of the problem to create a new feature or presentation of the domain. The speaker also outlines their work in applying machine learning to multiple steps in the drug development process, including target identification, molecule creation, and patient segmentation for clinical trials.

• Digital biology is the synthesis of data and quantitative biology, enabling the measurement of biology in new ways and scales
• End-to-end learning involves creating a new feature or presentation of the domain by reducing the dimensionality of the problem
• Machine learning is applied to multiple steps in the drug development process, including target identification, molecule creation, and patient segmentation for clinical trials